Active Ingredient History

NOW
  • Now
Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.   Wikipedia

More Chemistry
alpha-ethoxy-4-(2-(2-methyl-5-(4-methylthio)phenyl))-1h-pyrrol-1-yl)ethoxy))benzenepropanoic acid | alpha-ethoxy-4-(2-(2-methyl-5-(4-methylthio)phenyl))-1h-pyrrol-1-yl)ethoxy))benzenepropanoic acid magnesium salt | lipaglyn | saroglitazar | saroglitazar magnesium | slv337 | zyh1 | zyh1 compound

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue